The Food and Drug Administration (FDA) has approved Romvimza ™ (vimseltinib) for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will ...
News Medical on MSN4d
Vimseltinib Approved by FDA for Tenosynovial Giant Cell TumorThe FDA has approved vimseltinib for tenosynovial giant cell tumor (TGCT) based on the phase 3 MOTION trial led by Dr.
FDA approves vimseltinib for tenosynovial giant cell tumor and a triplet for R/R LBCL, plus the latest from ASCO GU 2025.
Becoming the second drug approved by the U.S. FDA for tenosynovial giant cell tumors, Deciphera Pharmaceuticals Inc.’s oral ...
Feb. 18, 2025 — The FDA has approved vimseltinib, a new oral drug for a rare, noncancerous tumor of the joints known as tenosynovial giant cell tumor (TGCT). It is intended for adults with ...
Ono picked up Romvimza—previously known by its active ingredient vimseltinib—from its $2.4 billion acquisition of Deciphera ...
Discover Vimseltinib, the newly FDA-approved treatment for tenosynovial giant cell tumor (TGCT). Learn about its benefits, ...
The US Food and Drug Administration has approved vimseltinib (Romvimza, Deciphera Pharmaceuticals, LLC) to treat adult ...
Vimseltinib is now an FDA-approved treatment for patients with tenosynovial giant cell tumor, based on findings from the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback